The Third Affiliated Hospital of Southern Medical University - Department of Nephrology, Guangzhou - China.
Capital Medical University - Department of Epidemiology and Biostatistics, Beijing - China.
Arq Bras Cardiol. 2022 Jun 10;118(6):1134-1140. doi: 10.36660/abc.20201383. eCollection 2022.
Atherosclerosis is the most common cause of cardiovascular disease globally, associated with a high incidence of clinical events. Accumulating evidence has elucidated that long non-coding RNAs (lncRNAs) as a novel class of transcripts with critical roles in the pathophysiological processes of atherosclerosis. In this review, we summarize the recent progress of lncRNAs in the development of atherosclerosis. We mainly describe the diverse regulatory mechanisms of lncRNAs at the transcriptional and post-transcriptional levels. This study may provide helpful insights about lncRNAs as therapeutic targets or biomarkers for atherosclerosis treatment.
动脉粥样硬化是全球范围内最常见的心血管疾病病因,与临床事件的高发相关。越来越多的证据表明,长链非编码 RNA(lncRNA)作为一类新型转录物,在动脉粥样硬化的病理生理过程中具有关键作用。在这篇综述中,我们总结了 lncRNA 在动脉粥样硬化发展中的最新进展。我们主要描述了 lncRNA 在转录和转录后水平的多种调节机制。这项研究可能为 lncRNA 作为动脉粥样硬化治疗的治疗靶点或生物标志物提供有价值的见解。